The patient-specific nature of autologous cell therapies presents unique challenges that can best be addressed by a middle path between on-site and centralized manufacturing.

In recent decades, sensor-less cars that rely on human decision-making have evolved into self-driving taxis that arrive on demand. Beate Mueller-Tiemann, PhD, CTO of the global CDMO Cytiva, points to ...

An executive order seeking to stop banks from discriminating against customers could be undermined by the administration’s gutting of the Consumer Financial Protection Bureau, which had been ...

Doubts about the colossal AUKUS military deal are growing. But Donald Trump’s protection-racket tactics and a subservient ...

Issuers have reason to watch the market closely, according to S&P Global Market Intelligence reports. U.S. credit card charge ...

That's why I spoke with Jeff DiLullo, CEO of Philips North America, for this week's Pulse Check feature. Philips announced a ...

Readers also comment on a divided America, Trump's use of the National Guard, Democratic and Republican Party policy and RFK ...

This week’s Current Climate newsletter also looks at a new funding for California’s bullet train and Norfolk Southern’s ...